Literature DB >> 17303584

Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1.

Bárbara Tazón-Vega1, Mireia Vilardell, Laureano Pérez-Oller, Elisabet Ars, Patricia Ruiz, Olivier Devuyst, Xose Lens, Patricia Fernández-Llama, José Ballarín, Roser Torra.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a systemic disorder with a wide spectrum of renal involvement. Differences in the age at onset of end-stage renal disease (ESRD) are partially explained by the genetic heterogeneity of the disease but intrafamilial variability remains to be explained. Modifier genes may play a role in disease severity.
METHODS: A total of 355 PKD1 patients from 131 families belonging to three different European centres were analysed. According to the age at onset of ESRD patients were classified into two groups: early and late onset. Two different cut-offs were used. Based on literature, early onset was firstly considered when ESRD was reached before 40 years of age and late onset after 60 years of age. Secondly, according to the bimodal distribution of age at onset of ESRD in our population we established two groups with similar variability and the cut-offs were assigned before 48 years of age and after 56 years of age. These groups of patients were then analysed by two different complementary perspectives: (i) using ESRD onset as a quantitative trait when performing survival analysis and Cox regression analysis, and (ii) considering it a qualitative trait. The candidate genes (and polymorphisms) studied were the following: NOS3 (T-786C and E298D), BDKRB1 (-699 G > C), BDKRB2 (R14C), TGFB1 (-509 C > T, R25P and L10P), ACE (I/D), EGFR (IVS1CA) and PKD2 (-9780 G > A, -718 A > G and 83 C > G).
RESULTS: The results disclosed that the ACE polymorphism had a slight influence on the age of onset of ESRD in ADPKD patients and the NOS3 and BDKBR1 polymorphisms showed a very slight involvement in renal outcome.
CONCLUSIONS: Our results discard the most prominent functional genes suggested to date, to have a major effect on ADPKD progression in this cohort. Genes strongly implicated in disease severity are yet to be identified. The description of such genes would allow us to establish a prognosis for ADPKD and eventually to develop therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303584     DOI: 10.1093/ndt/gfm036

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

2.  Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease.

Authors:  Ismail Kocyigit; Serpil Taheri; Elif Funda Sener; Aydin Unal; Eray Eroglu; Fahir Öztürk; Kezban Korkmaz; Gokmen Zararsiz; Hakan Imamoglu; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak
Journal:  Cardiorenal Med       Date:  2014-12-10       Impact factor: 2.041

Review 3.  Pharmacogenetics of new analgesics.

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 4.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02

5.  NOS3 gene intron 4 a/b polymorphism is associated with ESRD in autosomal dominant polycystic kidney disease patients.

Authors:  Udit Narayan Padhi; Madhubala Mulkalwar; Lakkakula Saikrishna; Henu Kumar Verma; Lvks Bhaskar
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

6.  Nitric oxide synthase and polycystic kidney disease.

Authors:  Viroj Wiwanitkit
Journal:  J Nephropharmacol       Date:  2015-06-20

7.  Human Evaluation of the Glu298Asp Polymorphism in NOS3 Gene and its Relationship with Onset age of ESRD in Iranian Patients Suffering from ADPKD.

Authors:  Negin Dasar; Sayyed Mohammad Hossein Ghaderian; Eznollah Azargashb
Journal:  Int J Mol Cell Med       Date:  2012
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.